Can avatrombopag (Su Kexin) be taken long-term to treat thrombocytopenia?

Avatrombopag (Avatrombopag) is an oral thrombopoietic drug primarily used to treat thrombocytopenia associated with chronic liver disease and thrombocytopenia caused by certain diseases or treatments. For most patients, the goal of using avatrombopag is to maintain platelet levels within a safe range to reduce the risk of bleeding, and does not necessarily require long-term continued use.

Clinically, the medication cycle of avatrombopag is usually adjusted based on the patient's platelet level and condition. Some patients can achieve safe platelet levels and avoid bleeding events with short-term use before surgery or interventional treatment. In such cases, the drug may only be used for a few days to a few weeks, and long-term use is not required.

For patients with chronic diseases, especially those with chronic liver disease who have persistently low platelets, avatrombopag can be used intermittently or for long-term maintenance according to dynamic changes in platelets. During long-term use, patients need to regularly monitor platelet levels to avoid the risk of blood clots caused by excessive platelet elevation. At the same time, doctors will adjust dosage or discontinuation plans based on individual differences to ensure safety.

In short, whether to take avatrombopag long-term depends on the patient's specific condition and control of platelet levels. Some patients can achieve therapeutic goals with short-term use, while patients with chronic thrombocytopenia may require intermittent or long-term maintenance medication. During use, you should strictly follow the doctor's instructions and regularly monitor blood routine and related indicators to ensure both efficacy and safety.

Reference materials:https://www.drugs.com/